Strategy

Executives are exploring various strategies to prepare for an uncertain pricing environment in the coming months and years.

Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just endure—but rise above—the current age of industry disruption.

Despite steady innovation and solid new drug approvals, the first half of 2025 was marked by a break from historical norms in financing, stock performance, and M&A for the pharma and biotech sectors.

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

Access inequity is a multitude of smaller, interconnected operational and bureaucratic challenges.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co-pay for a specific product.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.

The regulatory environment has become increasingly supportive of multi-indication development.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Both community and academic delivery models play essential and complementary roles in expanding CGT access.

Nurse practitioners and physician associates are two of the fastest growing clinician groups.

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Olympia Pharmaceuticals’ co-founders discuss how they’re pivoting in light of FDA’s decision.

New technologies and external factors are forcing companies to rethink financial planning and analysis.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

35 years of manufacturer rebates by any other name.

For a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.

These diseases require specialty treatment typically unavailable at local retail pharmacies or small health systems, making it extremely difficult for many patients to get the care they need.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

The traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.

Meeting the growing need and demand for fast information to make optimal and timely treatment decisions.

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.